acquired
Stage
About
LEX Diagnostics developed the NULEXA ultra-fast multiplex PCR point-of-care system that rapidly detects and differentiates respiratory pathogens including Influenza A/B and SARS-CoV-2, delivering fully automated swab-to-result diagnostics in under 10 minutes with CLIA-waived approval for use in physician offices, pharmacies, and urgent care facilities.
Explore LEX Diagnostics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.